超治疗剂量洛哌丁胺的毒性特征:系统评价与剂量-反应分析
该系统评价纳入129例超治疗剂量(>16 mg/日)洛哌丁胺暴露病例,中位日剂量200 mg,中位血药浓度87 µg/L,91%为慢性或亚急性暴露。严重病例占64%,主要表现为多形性(55%)或持续性单形性(40%)室性心动过速;死亡13%。严重性与剂量独立相关(每10 mg调整OR 1.04,95%CI 1.01-1.07),中位严重毒性剂量(TD50)估计为85 mg(95%CI 12-230 mg),低至20-40 mg/日即可发生严重毒性。死亡率与浓度正相关(每10 µg/L调整OR 1.07,95%CI 1.01-1.16),中位致死浓度(LC50)估计为210 µg/L(95%CI 70-436 µg/L)。作者认为该人群应广泛考虑密切心脏监测。
要点
- 超治疗剂量洛哌丁胺严重病例占64%(83/129),以多形性(55%)或持续性单形性(40%)室性心动过速为主要表现,死亡13%(17/129)。
- 严重性与剂量独立相关(每10 mg调整OR 1.04,95%CI 1.01-1.07),低至20-40 mg/日即可发生严重毒性,中位严重毒性剂量(TD50)估计为85 mg(95%CI 12-230 mg)。
- 死亡率与血药浓度正相关(每10 µg/L调整OR 1.07,95%CI 1.01-1.16),中位致死浓度(LC50)估计为210 µg/L(95%CI 70-436 µg/L)。
- 心动过缓与严重性独立相关(调整OR 4.96,95%CI 1.83-15.45);QRS延长与血药浓度正相关,但与剂量无关。
- 作者认为该人群应广泛考虑密切心脏监测;处理包括抗心律失常药物、电复律/除颤、起搏及机械生命支持。
适用人群与场景
- 人类超治疗剂量洛哌丁胺暴露(定义为>16 mg/日或依据浓度定义)的病例报告和病例系列。
- 排除临床病程或结局数据缺失的病例,以及远程或不清楚的暴露(如病史不一致或洛哌丁胺浓度不可测)。
- 纳入129例,中位年龄31岁(IQR 26-39),66%(n=85)男性,57%(n=73)有已知或疑似物质使用障碍,91%(n=117)为慢性或亚急性暴露。
诊断标准与关键阈值
- 超治疗剂量洛哌丁胺暴露定义:>16 mg/日或依据浓度定义。
- 主要结局为二分类严重性终点;次要结局包括五级中毒严重度评分(Poisoning Severity Score)、最大QTc和QRS时限。
处置流程与药物剂量
- 药物治疗最常见为镁剂(26%,n=34)、碳酸氢钠(23%,n=30)和异丙肾上腺素(20%,n=26)。
- 非药物治疗包括电复律/除颤(20%,n=26)、起搏(15%,n=19)和机械生命支持(4%,n=5)。
- 作者认为该人群应广泛考虑密切心脏监测;处理选项包括适当的抗心律失常和心脏循环支持措施。
红旗征与不能漏的情况
- 晕厥(45%,n=58)常被报告。
- 严重病例(64%,n=83)主要特征为多形性(55%,n=46)或持续性单形性(40%,n=33)室性心动过速。
- 心动过缓与严重性独立相关(调整OR 4.96,95%CI 1.83-15.45)。
- 低至20-40 mg/日即可发生严重毒性。
- 死亡率与血药浓度正相关(每10 µg/L调整OR 1.07,95%CI 1.01-1.16)。
研究设计与关键结果
- 系统评价纳入129例病例报告和病例系列;中位日剂量200 mg(IQR 113-343,n=112),中位血药浓度87 µg/L(IQR 33-210,n=39)。
- 严重病例占64%(n=83),死亡13%(n=17);典型阿片类毒性体征仅12%(n=16)报告。
- 严重性与剂量独立相关(每10 mg调整OR 1.04,95%CI 1.01-1.07),中位严重毒性剂量(TD50)估计为85 mg(95%CI 12-230 mg)。
- 死亡率与浓度正相关(每10 µg/L调整OR 1.07,95%CI 1.01-1.16),中位致死浓度(LC50)估计为210 µg/L(95%CI 70-436 μg/L)。
- 心动过缓与严重性独立相关(调整OR 4.96,95%CI 1.83-15.45);QRS延长与血药浓度正相关,但与剂量无关。
- 为增加洛哌丁胺暴露而故意共摄入物质者占5%(n=6,均为西咪替丁)。
证据类型、等级与局限
- 证据类型:系统评价与剂量-反应分析,基于病例报告和病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为超治疗剂量洛哌丁胺暴露患者存在危及生命的心律失常高风险,应广泛考虑密切心脏监测。
- 作者指出严重毒性风险在低于既往认识的剂量下即存在,提示即使中等超治疗剂量也可能需要心脏监测。
- 阿片类毒性典型体征不常见(12%),不能以此排除严重心脏毒性。
- 处理选项包括适当的抗心律失常和心脏循环支持措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Life-threatening cardiotoxicity resulting from supratherapeutic loperamide exposure (i.e., >16 mg per day) has been increasingly reported in recent years. However, systematic data on the toxicity profile and dose-response relationship are lacking.
METHODS: We conducted a systematic review of publications on supratherapeutic loperamide exposure in humans, defined by dose or concentration, and identified through database (Medline/Pubmed, Embase, and Scopus), citation, and conference abstract searches. Cases with missing data on clinical course or outcome, as well as remote or unclear exposures (e.g., inconsistent history or undetectable loperamide concentration) were excluded. The database search strategy employed a combination of search terms encompassing the substance, the context of use and signs of toxicity. The primary outcome was a binary severity endpoint. Secondary outcomes included the five-level Poisoning Severity Score, as well as the maximum QTc and QRS durations. Regression models were used to examine exposure-toxicity relationships, adjusting for demographics, comorbidities, co-ingestions, electrolyte imbalances and bradycardia.
RESULTS: We included 129 cases (median age 31 years (IQR 26-39), 66% (n = 85) male, 57% (n = 73) with known or suspected substance use disorder) from case reports and case series. The median daily ingested dose was 200 mg (IQR 113-343, n = 112) and the median blood concentration was 87 µg/L (IQR 33-210, n = 39). Most cases (91%, n = 117) were chronic or subacute exposures. Purposeful co-ingestion of substances in order to increase loperamide exposure was reported in 5% cases (n = 6, all cimetidine). Syncope was frequently reported (45%, n = 58). Severe cases (64%, n = 83) were mainly characterized by polymorphic (55%, n = 46) or sustained monomorphic (40%, n = 33) ventricular tachycardias. Typical signs of opioid toxicity were reported in 12% (n = 16) of the cases. Severity was dose-dependent (adjusted OR 1.04, 95% confidence interval (CI) 1.01-1.07, per 10 mg), with severe toxicity occurring at doses as low as 20-40 mg/day and a median severe toxicity dose (TD50) estimated at 85 mg (95% CI 12-230 mg). Fatalities were reported in 13% of the cases (n = 17) and mortality was positively associated with concentration (adjusted OR 1.07, 95% CI 1.01-1.16, per 10 µg/L), with a median lethal concentration (LC50) estimated at 210 µg/L (95% CI 70-436 μg/L). Bradycardia was independently associated with severity (adjusted OR 4.96, 95% CI 1.83-15.45), and QRS prolongation was positively associated with plasma concentration but not dose. Pharmacologic treatments included most commonly magnesium (26%, n = 34), sodium bicarbonate (23%, n = 30) and isoproterenol (20%, n = 26), while non-pharmacologic interventions included cardioversion/defibrillation (20%, n = 26), pacing (15%, n = 19), and mechanical life support (4%, n = 5).
DISCUSSION: In case reports and case series, supratherapeutic loperamide was associated with dose-dependent cardiotoxicity; classical signs of opioid toxicity, however, were uncommon. There was considerable risk for severe toxicity at lower doses than previously appreciated, suggesting cardiac monitoring might be indicated even at modestly supratherapeutic doses. Bradycardia and loperamide dose were independent risk factors for severe outcomes and mortality was positively associated with concentration. Management included various pharmacologic and non-pharmacologic rhythm control interventions and invasive mechanical life support in a few cases.
CONCLUSION: Patients presenting with supratherapeutic loperamide exposure appear to be at high risk for life-threatening dysrhythmias, and close cardiac monitoring should be broadly considered in this population. Management options include appropriate antiarrhythmic and cardiocirculatory support measures.
参考来源
- Bekka E, Martinez-De la Torre A, Haschke M, et al. Toxicity profile of supratherapeutic loperamide: a systematic review and dose-response analysis. Clin Toxicol (Phila). 2026. PMID: 41817965. doi:10.1080/15563650.2026.2634757
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。